A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：12
|
作者：
Verstovsek, Srdan [1 ]
Pardanani, Animesh D. [2 ]
Shah, Neil P. [3 ]
Sokol, Lubomir [4 ]
Wadleigh, Martha [5 ]
Gilliland, D. Gary
List, Alan F. [4 ]
Tefferi, Ayalew [2 ]
Kantarjian, Hagop M. [1 ]
Bui, Lynne A. [6 ]
Clary, Douglas O. [6 ]
机构：
[1] MD Anderson Canc Ctr, San Francisco, CA USA
[2] Mayo Clin, San Francisco, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, San Francisco, CA USA
[5] Dana Farber Canc Inst, San Francisco, CA USA
[6] Exelixis Inc, San Francisco, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.553.553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
553
引用
收藏
页码：170A / 170A
页数：1
相关论文
共 50 条
  • [31] Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Mora, Barbara
    Guglielmelli, Paola
    Kuykendall, Andrew
    Rumi, Elisa
    Maffioli, Margherita
    Palandri, Francesca
    De Stefano, Valerio
    Caramella, Marianna
    Salmoiraghi, Silvia
    Kiladjian, Jean-Jacques
    Gotlib, Jason
    Iurlo, Alessandra
    Cervantes, Francisco
    Ruggeri, Marco
    Silver, Richard T.
    Albano, Francesco
    Benevolo, Giulia
    Ross, David M.
    Della Porta, Matteo G.
    Devos, Timothy
    Rotunno, Giada
    Komrokji, Rami S.
    Casetti, Ilaria C.
    Merli, Michele
    Brociner, Marco
    Caramazza, Domenica
    Auteri, Giuseppe
    Barbui, Tiziano
    Cattaneo, Daniele
    Bertu, Lorenza
    Arcaini, Luca
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    LEUKEMIA, 2022, 36 (10) : 2453 - 2460
  • [32] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [33] The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
    Ikeda, Kazuhiko
    Ueda, Koki
    Sano, Takahiro
    Ogawa, Kazuei
    Ikezoe, Takayuki
    Hashimoto, Yuko
    Morishita, Soji
    Komatsu, Norio
    Ohto, Hitoshi
    Takeishi, Yasuchika
    INTERNAL MEDICINE, 2017, 56 (13) : 1705 - 1710
  • [34] Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Barbara Mora
    Paola Guglielmelli
    Andrew Kuykendall
    Elisa Rumi
    Margherita Maffioli
    Francesca Palandri
    Valerio De Stefano
    Marianna Caramella
    Silvia Salmoiraghi
    Jean-Jacques Kiladjian
    Jason Gotlib
    Alessandra Iurlo
    Francisco Cervantes
    Marco Ruggeri
    Richard T. Silver
    Francesco Albano
    Giulia Benevolo
    David M. Ross
    Matteo G. Della Porta
    Timothy Devos
    Giada Rotunno
    Rami S. Komrokji
    Ilaria C. Casetti
    Michele Merli
    Marco Brociner
    Domenica Caramazza
    Giuseppe Auteri
    Tiziano Barbui
    Daniele Cattaneo
    Lorenza Bertù
    Luca Arcaini
    Alessandro M. Vannucchi
    Francesco Passamonti
    Leukemia, 2022, 36 : 2453 - 2460
  • [35] Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Newberry, Kate J.
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [36] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis
    Guy, Alexandre
    Bidet, Audrey
    Ling, Catherine
    Caumont, Charline
    Boureau, Lisa
    Viallard, Jean-Francois
    Parrens, Marie
    VIRCHOWS ARCHIV, 2021, 479 (04) : 755 - 764
  • [37] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis
    Alexandre Guy
    Audrey Bidet
    Catherine Ling
    Charline Caumont
    Lisa Boureau
    Jean-François Viallard
    Marie Parrens
    Virchows Archiv, 2021, 479 : 755 - 764
  • [38] Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval G.
    Pemmaraju, Naveen
    Newberry, Kate J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [39] A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
    Andersen, Christen L.
    Mortensen, Nana B.
    Klausen, Tobias W.
    Vestergaard, Hanne
    Bjerrum, Ole W.
    Hasselbalch, Hans C.
    HAEMATOLOGICA, 2014, 99 (01)
  • [40] A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis
    DeAngelo, D. J.
    Tefferi, A.
    Mesa, R. A.
    Paley, C. S.
    Wadleigh, M.
    Snyder, D.
    Ondovik, M. S.
    Rine, J.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345